PIK3CA and neoplasm: On the mice xenografted with patient-derived tumor (carrying exon 19 deletion mutation, with or without co-occurrence of PIK3CA mutation), either treated with gefitinib or untreated and based on the dynamics observed in literature, the ISELA model reproduces accurately the evolution of tumor volume over time (Fig. 2c–f).